NeurAxis, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a medical technology company built around PENFS neuromodulation. Its 8-K reports cover preliminary operating results, FDA 510(k) clearance for PENFS indications, at-the-market common stock offering arrangements under a Form S-3 registration statement, related prospectus supplements and legal opinions, and material agreements involving licensed neuromodulation assets.
NeurAxis proxy materials disclose annual meeting matters, director elections, auditor ratification, equity incentive plan amendments, an employee stock purchase plan, and voting rights involving common stock and Series B Preferred Stock. The filing record also documents corporate governance, stock-based compensation plans, material contract changes, and risk-bearing financing mechanisms tied to its commercialization strategy.
Thomas Joeseph Carrico, an officer of Neuraxis, Inc. (NRXS), received three awards of restricted stock units (RSUs) totaling 72,435 shares across transaction dates of 01/03/2025 and 03/04/2025. The grants are recorded as non‑derivative/derivative entries converting to common stock at reported per‑share values of $2.18 and $2.42 depending on the grant.
The RSUs are described as bonus and long‑term incentive awards under the company’s equity plans and will vest in full at the end of 36 months, meaning Carrico will obtain the underlying common shares only after the three‑year vesting period. The filing shows the awards are held directly by the reporting person.
Neuraxis, Inc. has entered into an At-The-Market (ATM) Offering Agreement with Craig-Hallum Capital Group LLC that allows the company to offer and sell shares of its common stock, at the company's discretion, through the sales agent. The agreement permits aggregate sales with an offering price up to $3,300,000. The arrangement gives Neuraxis a standing mechanism to raise capital by selling shares into the market over time rather than through a single underwritten offering.
This filing discloses the existence and terms of the sales-agent relationship and the maximum aggregate offering amount; no specific sales, pricing, or use-of-proceeds details are included in the provided text.
Neuraxis, Inc. is launching an at-the-market stock offering of up to $3,300,000 in common shares through Craig-Hallum Capital Group. The shares may be sold from time to time on the NYSE American or other U.S. trading markets at prevailing prices, with Craig-Hallum acting as sales agent or principal and earning a 3.0% commission on gross proceeds.
As of August 27, 2025, Neuraxis had 9,872,776 common shares outstanding, and assumes a reference price of $2.42 per share, the last reported sale price, for illustrative calculations. If the full amount is sold at that price, the company estimates its net tangible book value per share would rise from $0.40 to $0.62, implying dilution of $1.80 per share to new investors. Net proceeds are intended for capital expenditures, sales and marketing, and general working capital, with management retaining broad discretion over how the funds are allocated.
NeurAxis, Inc. reported quarterly net sales of $894,086, an increase of 46.2% versus the prior-year quarter, and six‑month net sales of $1.79 million. Cash rose by $2,291,586 to $5,988,456 at June 30, 2025, driven largely by proceeds of $4,999,999 from a May 22, 2025 common stock offering (1,538,461 shares issued) and $1,002,991 from warrant exercises.
Despite revenue growth and improved liquidity, the company reported a six‑month net loss of $3,969,102 and an accumulated deficit of $60,768,714. Management and auditors disclosed substantial doubt about the company’s ability to continue as a going concern. The company accrued a $375,000 current liability and $267,540 noncurrent liability for a tentative $750,000 litigation settlement. Series B Preferred Stock outstanding totaled 3,896,907 shares and common shares outstanding were 9,858,716 as of June 30, 2025.
Neuraxis, Inc. (NRXS) Form 4 filing shows Director and 10% owner Brian P. Hannasch purchased 355,556 common shares on 07/01/2025 at $2.25 per share, an estimated cash outlay of roughly $0.8 million. The transaction was coded “P” (open-market purchase), executed directly, and lifts Hannasch’s total direct holdings to 1,131,522 shares.
Key take-aways:
- The purchase represents a sizable vote of confidence by a control insider.
- Post-transaction ownership exceeds one million shares, reinforcing alignment with minority shareholders.
- No disposals or derivative transactions were reported.
The filing contains no additional financial data or explanatory notes beyond the standard certification.